February 2024:
Glycologix receives notice of second issued US patent
October 2023:
Glycologix Treats First Patient in Pilot Study of GLX-100 for Treatment of Interstitial Cystitis/Bladder Pain Syndrome
May 2021:
Glycologix receives notice of issued US patent
January 2021:
Dan Deardorf joins Glycologix as President and Chief Executive Officer
October 2020:
Glycologix receives notice of issued Australian patent
July 2020:
Rich Heidebrecht, PhD, joins Glycologix as Vice President of Research and Development
June 2020:
Glycologix awarded $2M NIH SBIR Phase II grant
June 2018:
Glycologix awarded $287K NIH SBIR Phase I grant
March 2018:
Lead patent published under Patent Cooperation Treaty (PCT)
March 2016:
Glycologix founded
Medicinal Chemistry Strategy Meeting East Coast 2024
Speaker/ Facilitator, Rich Heidebrecht, VP R+D